Risks
4 risks
Risk Intelligence
USFDA plant clearances delayed
View Risks →Biocon Limited — Q2 FY25
Biocon's Q2 FY25 consolidated revenue from operations grew 8% YoY to ₹3,590 crore, driven by biosimilars (up 19% like-for-like) but offset by generics decline (-8%) and flat Syngene performance.
neutral
medium
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Biocon's Q2 FY25 consolidated revenue from operations grew 8% YoY to ₹3,590 crore, driven by biosimilars (up 19% like-for-like) but offset by generics decline (-8%) and flat Syngene performance. Group EBITDA margin was 20%, with core EBITDA at 28%. Reported net loss of ₹16 crore reflected higher tax and minority interest. Biosimilars saw strong US market share gains (Ogivry 18%, Fulphila 21%) and successful $1.1B debt refinancing. Generics faced pricing pressure but expects H2 recovery from Liraglutide UK launch and new injectables. Syngene showed early recovery signs with 13% sequential growth. Management reiterated H2 acceleration guidance. Key risk: USFDA plant clearances for Bengaluru and Malaysia facilities remain pending, delaying key biosimilar launches like Aspart and Bevacizumab.
बायोकॉन की दूसरी तिमाही में कुल कमाई पिछले साल से 8% बढ़कर ₹3,590 करोड़ हो गई। इसकी मुख्य वजह बायोसिमिलर (महंगी दवाओं के सस्ते विकल्प) की बिक्री में 19% का उछाल था, लेकिन जेनेरिक दवाओं की बिक्री 8% गिर गई और सायनजीन का प्रदर्शन सपाट रहा। कंपनी का मुनाफा मार्जिन 20% रहा, जबकि असली मुनाफा 28% था। कुल मिलाकर ₹16 करोड़ का घाटा हुआ, जो ज्यादा टैक्स और माइनॉरिटी हिस्सेदारी के कारण था। अमेरिका में बायोसिमिलर दवाओं (Ogivry और Fulphila) की बाजार हिस्सेदारी बढ़ी और कंपनी ने $1.1 बिलियन का कर्ज सस्ती दरों पर बदला। जेनेरिक दवाओं पर कीमत दबाव है, लेकिन साल की दूसरी छमाही में नई दवाओं (Liraglutide) के लॉन्च से सुधार की उम्मीद है। सायनजीन में पिछली तिमाही से 13% बढ़त दिखी। प्रबंधन ने साल की दूसरी छमाही में तेजी का अनुमान दोहराया। मुख्य जोखिम: अमेरिकी स्वास्थ्य एजेंसी (USFDA) से बेंगलुरु और मलेशिया फैक्ट्रियों की मंजूरी अटकी है, जिससे नई बायोसिमिलर दवाओ
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Ogivry US market share
18%
+7pp YoY
Biosimilar Trastuzumab market share increased from 11% to 18% year-on-year.
Fulphila US market share
21%
+6pp YoY
Biosimilar Pegfilgrastim market share rose from 15% to 21% year-on-year.
Biocon Biologics net debt
$1.27B
-$50M QoQ
Net debt reduced by about $50 million from previous quarter to $1.27 billion.
Syngene audits conducted
60+
+36% YoY
Syngene completed over 60 audits in H1, a 36% increase versus same period last year.
What Changed vs Last Quarter
NEW
Generics mid-teens growth over next couple of years
Generics business targets mid-teens revenue growth over the next two years, driven by peptides, new OSDs, and injectables.
UPDATED
H2 FY25 acceleration in growth
Management expects a transition to accelerated growth in H2, driven by Syngene returning to growth, maintained biosimilars momentum, and generics recovery from new launches.
UPDATED
Liraglutide launch in UK in Q3 FY25
First generic Liraglutide approved in UK; launch expected in Q3 FY25, contributing to generics recovery.
UPDATED
Ustekinumab launch in US in Q4 FY25
Biocon Biologics expects to launch biosimilar Ustekinumab in the US in Q4 FY25, pending FDA approval.
DROPPED
Generics high single-digit growth for FY25
Generics business is expected to deliver high single-digit revenue growth for the full year, with H2 significantly stronger than H1.
DROPPED
Debt reduction priority
Management intends to reduce debt further during FY25, following a $250 million reduction last year, but no specific timeline or amount was provided.
NEW RISK
USFDA plant clearances delayed
Bengaluru and Malaysia facilities have pending USFDA inspections; delays could impact Aspart, Bevacizumab, and other biosimilar launches in the US.
NEW RISK
Humira biosimilar market share growth slow
Despite market share gains, Humira biosimilar adoption has been slower than expected; pricing competition may limit upside.
NEW RISK
High net debt and capex outflows
Consolidated net debt increased to $1.4 billion despite refinancing; high capex (~₹900 crore in H1) may pressure free cash flow.
RISK GONE
US FDA inspection outcomes
The US FDA issued 10 observations (Form 483) at Biocon Park facilities in Bengaluru; while procedural, resolution timing is uncertain and could impact new product approvals.
RISK GONE
Aflibercept litigation delays
Ongoing patent litigation with the innovator in the US may delay commercialization of aflibercept, despite FDA approval and interchangeable status.
RISK GONE
Debt servicing and refinancing risk
Net debt at BBL is ~$1.2 billion; while management is exploring options, no specific deleveraging plan was disclosed, raising concerns about interest costs.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
The U.S. Adalimumab biosimilar market is expected to open meaningfully only in CY2025, delaying potential revenue contribution from this large opportunity.
Mentioned in Q1 FY25, Q3 FY24, Q4 FY24
Management intends to reduce debt further during FY25, following a $250 million reduction last year, but no specific timeline or amount was provided.
Mentioned in Q1 FY25, Q3 FY24, Q4 FY24
The US FDA issued 10 observations (Form 483) at Biocon Park facilities in Bengaluru; while procedural, resolution timing is uncertain and could impact new product approvals.
Mentioned in Q1 FY24, Q2 FY24
Net debt to EBITDA elevated; interest costs rising due to high rate environment; deferred payments in FY25 may require additional funding.
Mentioned in Q1 FY24, Q1 FY25
Generics segment revenue declined 6% YoY due to pricing erosion and demand challenges; continued price erosion could pressure margins.
Fast read
Guidance and risk preview
Management expects a transition to accelerated growth in H2, driven by Syngene returning to growth, maintained biosimilars momentum, and generics r...
Bengaluru and Malaysia facilities have pending USFDA inspections; delays could impact Aspart, Bevacizumab, and other biosimilar launches in the US.
View Risks →